Summary
The aim of the NeoVitaA Trial is to assess the role of postnatal additional high-dose oral vitamin A supplementation for 28 days in reducing Bronchopulmonary dysplasia (BPD) or death in extremely low birth weight (ELBW) infants at 36 weeks postmenstrual age (PMA). All infants (both intervention and control group) will be provided with basic vitamin A (1000 IU/kg/day) in addition to trial intervention.
In this short communication, we will give an up-date on obstacles, challenges as well as perspectives and potential solutions when putting into place a multicenter, double-blind, randomized trial in this cohort of extremely susceptible infants.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10354-016-0500-z/MediaObjects/10354_2016_500_Fig1_HTML.gif)
Abbreviations
- BPD:
-
Bronchopulmonary dysplasia
- CPAP:
-
Continuous positive airway pressure
- DGKJ:
-
Deutsche Gesellschaft für Kinderheilkunde und Jugendmedizin
- ELBW:
-
Extremely low birth weight
- GNPI:
-
Gesellschaft für Neonatologische und Pädiatrische Intensivmedizin
- HFOV:
-
High frequency oscillatory ventilation
- iNO:
-
inhalative nitric oxide
- IZKS:
-
Interdisziplinäres Zentrum für Klinische Studien (Mainz)
- NICHD:
-
National Institute of Child Health and Human Development
- PMA:
-
Postmenstrual age
- PPV:
-
Positive pressure ventilation
- PPS:
-
Positive pressure support
- RCT:
-
Randomized controlled trial
- ZKS:
-
Zentrum für Klinische Studien (Tübingen)
References
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–9.
Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF, Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the Trial of Indomethacin Prophylaxis in Preterms. JAMA. 2003;289:1124–9.
Marter LJ van, Kuban KC, Allred E, Bose C, Dammann O, O’Shea M, Laughon M, Ehrenkranz RA, Schreiber MD, Karna P, Leviton A, ELGAN Study Investigators. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation? Arch Dis Child Fetal Neonatal Ed. 2011;96:F20–F29.
Stichtenoth G, Demmert M, Bohnhorst B, Stein A, Ehlers S, Heitmann F, Rieger-Fackeldey E, Olbertz D, Roll C, Emeis M, Mögel M, Schiffmann H, Wieg C, Wintgens J, Herting E, Göpel W, Härtel C. Major contributors to hospital mortality in very-low-birth-weight infants: data of the birth year 2010 cohort of the German Neonatal Network. Klin Padiatr. 2012;224:276–81.
Gortner L, Misselwitz B, Milligan D, et al. Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort. Neonatology. 2011;99:112–7.
Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, Richardson DK. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr. 2005;146:469–73.
Thomas W, Speer CP. Management of infants with bronchopulmonary dysplasia in Germany. Early Hum Dev. 2005;81:155–63.
Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D, Greenough A, Overmeire B van, Jonsson B, Hallman M, Baldassarre J, EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet. 2010;376:346–54.
Watterberg KL, American Academy of Pediatrics. Committee on fetus and newborn policy statement – postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 2010;126:800–8.
Röhr SB, Sauer H, Gortner L, Gräber S, Meyer S. Cardiovascular and metabolic side effects associated with hydrocortisone and dexamethasone use in VLBW infants: a single-centre experience. Acta Paediatr. 2013;102:e436.
Biesalski HK, Nohr I. Importance of vitamin A for lung function and development. Mol Aspects Med. 2003;24:431–40.
Metzler MD, Snyder JM. Retinoic acid differentially regulates expression of surfactant associated proteins in human fetal lung. Endocrinology. 1993;133:1990–8.
Zile MH. Function of vitamin A in vertebrate embryonic development. J Nutr. 2001;131:705–8.
Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev. 2011;10:CD000501.
Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999;340:1962–8.
Kaplan HC, Tabangin ME, McClendon D, Meinzen-Derr J, Margolis PA, Donovan EF. Understanding variation in vitamin A supplementation among NICUs. Pediatrics. 2010;126:e367–e373.
Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2009;50:85–91.
Wardle SP, Hughes A, Chen S, Shaw NJ. Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2001;84:F9–F13.
Gadhia MM, Cutter GR, Abman SH, Kinsella JP. Effects of early inhaled nitric oxide therapy and vitamin A supplementation on the risk for bronchopulmonary dysplasia in premature newborns with respiratory failure. J Pediatr. 2014;164:744–8.
Meyer S, Gortner L. NeoVitaA Trial Investigators Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. Neonatology. 2014;105:182–8.
Collaborators
NeoVitaA Trial investigators: Sascha Meyer, Johannes Bay, Ludwig Gortner; IZKS Mainz: Anne Ehrlich, Christian Ruckes; Elisabeth-Children’s Hospital Oldenburg: Jürgen Seidenberg, Julia Muyimbwa; Children’s Hospital Aschaffenburg: Christian Wieg, Oliver Stangl; Department of Pediatrics, University of Magdeburg: Ralf Böttger, Stefan Avenarius; University Children’s Hospital Erlangen: Thomas Völkl, Hans-Georg Topf; University Children’s Hospital, RWTH Aachen: Konrad Heimann, Sonja Trepels-Kottek; Children’s Hospital Barmherzige Brüder Regensburg: Annette Keller-Wackerbauer, Jochen Kittel; Children’s Hospital Mutterhaus, Trier: Wolfgang Thomas, Andrea Czoske; University Children’s Hospital of Munich: Orsolya Genzel-Boroviczény, Raquel Mata Fernandez; University Children’s Hospital of Münster: Torsten Ott, Claudius Werner; University Children’s Hospital of Münster: Ursula Felderhoff-Müser, Anja Stein; Evangelical Children’s Hospital of Oberhausen: Eva Hahn, Andreas Jenke; Helios Hospital Wiesbaden: Jaqueline Bauer, Markus Knuf; Winterberg Hospital Saarbrücken: Donald Wurm, Jens Möller; Universitätsklinikum Heidelberg: Bernd Beedgen, Johannes Pöschl; Westpfalz Klinikum Kaiserslautern: Kathrin Fritsche, Claudia Jung; Neonatal Intensive Care Unit, University Children´s Hospital Bonn: Andreas Müller, Lars Wenzing; Universitätskinderklinik Bochum: Susanne Wiegand, Norbert Teig; Neonatal Intensive Care Unit, University Children´s Hospital Tübingen: Axel Franz, Christian Poets; Universitätskinderklinik Leipzig: Corinna Gebauer, Ulrich Thome; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna: Angelika Berger, Alexandra Kreissl; Sana Klinikum Duisburg: Tina Mönig, Francisco Brevis Nuñez; Helios Klinikum Wuppertal: Stephan Lysko, Gediz Taskaya; Diakonie Klinikum Dattelsau, Nürnberg: Nicole Holzgartner, Michael Schroth; Department für Kinder- und Jugendheilkunde, Medizinische Universität Innsbruck: Ursula Kiechl, Vera Neubauer; NICU Marburg: Michael Zemlin, Rolf F. Maier; NICU Gießen: Harald Ehrhardt, Lars Klein; Neonatal Intensive Care Unit, University Children’s Hospital Mannheim: Julia Reinhard, Thomas Schaible; Zentrum für Kinder- und Jugendmedizin, Neonatologische und Pädiatrische Intensivmedizin; Universität Greifswald: Knud Linnemann, Matthias Heckmann; Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University, Campus Homburg: Stefan Wagenpfeil; University Hohenheim, Stuttgart: Hans Konrad Biesalski, Donatus Nohr
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
S. Meyer, L. Gortner, and the NeoVitaA Trial investigators declare that they have no competing interests. The manuscript has been seen and approved by all contributing authors.
Ethical standards
The study has also been approved by all relevant state committees and local ethics committees.
Rights and permissions
About this article
Cite this article
Meyer, S., Gortner, L. & NeoVitaA Trial investigators. Up-date on the NeoVitaA Trial: Obstacles, challenges, perspectives, and local experiences. Wien Med Wochenschr 167, 264–270 (2017). https://doi.org/10.1007/s10354-016-0500-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-016-0500-z